PMH21 Cost-Effectiveness of Intramuscular Ziprasidone for the Treatment of Acute Agitation Associated to Schizophrenia in Mexico  by Galindo-Suárez, R.M. et al.
flecting real-life clinical practice based on structured interviews with experts.
METHODS: Six experts in the field of schizophrenia from different treatment
settings and regions in Germany were consulted. Structured interviews about
the treatment patterns and costs in selected outpatient and inpatient treatment
areas, e.g. psychiatrists, occupational therapists, day care units and acute psy-
chiatric wards, were conducted. Costs were assessed from the perspective of the
statutory health insurance. The assessment was divided into stable and relaps-
ing schizophrenic patients. Costs for the management of frequent side effects
were considered. RESULTS: The proportion of stable patients with schizophre-
nia was assessed to be 80% in Germany. Stable patients were estimated to have
1.5 psychiatrist contacts per quarter and relapsing patients were assessed to
have 6-8 contacts per quarter. Psychiatrist costs per quarter are varying be-
tween different regions in Germany, e.g. costs in Bavaria were €92 in 2011.
Inpatient costs per day in acute psychiatric wards are varying between €206 in
Baden-Württemberg and €244 in Saarland. CONCLUSIONS: The results of the
structured expert interviews will be used as input for cost-effectiveness models
in schizophrenia. In further studies the results should be verified in real-life
clinical practice.
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OBJECTIVES: Only few people with severe mental illness are able to obtain paid
work. Individual placement and support (IPS) is a vocational rehabilitation inter-
vention aimed at assisting people with severe mental illness in finding competitive
employment. This study assessed the balance between costs and outcomes of IPS
compared to regular vocational rehabilitation in people with severe mental illness
in the Netherlands. METHODS: An economic evaluation was conducted alongside
a multicenter RCT with a follow-up of 30 months. In total 151 people with severe
mental illness were randomly assigned to IPS or regular vocational rehabilitation-
(RVR). The primary outcome measure of the cost-effectiveness analysis was the
percentage of people with at least one day of paid work during the study. The
economic evaluation was conducted from a societal perspective. Costs and out-
comes were prospectively assessed during 30 months. The expectation maximisa-
tion algorithm with a bootstrap approach was applied to deal with missing cost
data. RESULTS: The percentage of people with paid work during the study was
significantly higher in the IPS group (44% versus 25% in RVR). There were no differ-
ences between groups in quality of life. Mean total costs were €57,285 in the IPS
group and €43,819 in the RVR group. Cost types that contributed considerably to the
total costs were related to hospital admissions, sheltered accommodations, and
informal care. The calculated incremental cost-effectiveness ratio was €1,084 per
percent of people with paid work gained. CONCLUSIONS: The study demonstrated
that IPS was associated with higher costs and better (work-related) outcomes in
people with severe mental illness. Decision makers will eventually have to decide
whether the described gains associated with IPS are worth the additional costs.
Generalizing current results to other countries may only be possible after carefully
comparing the various components of each health care system concerned.
PMH20
METABOLIC CONSEQUENCES AND COST-EFFECTIVENESS OF ASENAPINE IN
THE TREATMENT OF BIPOLAR DISORDER
Selya-Hammer C1, Gauthier A1, Millar HL2, Barnett AH3, Marre C4
1Amaris, London, UK, 2Mental Health Directorate, Dundee, UK, 3Birmingham Heartlands
Hospital, Birmingham, UK, 4Lundbeck S.A.S., Issy les Moulineaux, France
OBJECTIVES: Metabolic syndrome (MetS) is a medical condition that may arise
during exposure to antipsychotics and carries with it an increased risk of diabetes
and cardiovascular disease (CVD). Asenapine is the first tetracyclic antipsychotic to
treat manic episodes of Bipolar I Disorder (BD- I). In a head-to-head non-inferiority
trial versus olanzapine, post-hoc analyses illustrate the higher incidence of devel-
oping MetS with olanzapine than with asenapine, already after 12 weeks of treat-
ment. The aim of this study was to assess the cost-effectiveness of asenapine in the
treatment of BD-I manic episodes compared to atypical antipsychotics with a focus
on the long-term consequences of MetS over lifetime horizon. METHODS: A
Markov health-state cohort model was developed. Because similar efficacy in treat-
ing manic episodes was demonstrated in active controlled non-inferiority clinical
trial vs. olanzapine and through indirect comparisons with quetiapine and arip-
iprazole, only the consequences of MetS were considered for this model. The risks
of developing MetS after 12 weeks of treatment were derived from randomized
clinical trials. The subsequent risks of developing diabetes or cardiovascular dis-
ease were based on previously published risk models. The perspective of the UK
National Health Service (NHS) was applied and a lifetime horizon adopted. Deter-
ministic and probabilistic sensitivity analyses were conducted. RESULTS: Asenap-
ine dominates (more effective and less expensive) olanzapine, quetiapine and arip-
iprazole over lifetime horizon. Compared to treatment with generic olanzapine,
and branded aripiprazole and quetiapine, asenapine was associated with incre-
mental total costs of -£121, -£312 and -£560 respectively. Asenapine was associated
with Quality-Adjusted Life Year gains of 0.0569 compared to olanzapine and que-
tiapine, and 0.0038 compared to aripriprazole. CONCLUSIONS: The significant
lower incidence of developing MetS associated with asenapine compared to olan-
zapine, aripriprazole and quetiapine is associated with a lower incidence of diabe-
tes and CVD that results in lower subsequent treatment costs and improved mor-
bidity.
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OBJECTIVES: Acute agitation is a transient syndrome characterized by increase in
verbal and physical behavior, which results in aggression. In order to diminish the
risk of damage for both, caregivers and patients, fast response drugs are required.
The study is aimed to estimate the pharmacoeconomic profile of intramuscular
injections of haloperidol 5mg, olanzapine 10mg and ziprasidone 20mg for acute
agitation episodes associated with schizophrenia, from the perspective of a Mexi-
can public health institution. METHODS: A discrete event simulation model was
developed. The measure of effectiveness was the average time in which patients
reach control50%, regarding baseline level in the Overt Aggression Scales, with a
time horizon of 12 hours. Clinical efficacy was extracted from published literature.
A panel of experienced psychiatrists (n12) was used to estimate the medical
resource use profile. The model assesses direct medical costs (2012 US$) such as
drugs, specialist’s visits, laboratory tests and management of adverse events. The
results are reported in terms of ICER. Deterministic and probabilistic sensitivity
analyses were performed. RESULTS: The cost per patient for ziprasidone was $693,
it represents $198.6 and $64.6 less than the cost of haloperidol and olanzapine,
respectively. Differences in costs were driven by less specialist’s visits with ziprasi-
done and high incidence of akathisia and dystonia with haloperidol. The effective-
ness measure was accomplished by ziprasidone, olanzapine and haloperidol at
1.55h, 1.48h and 1.74h, respectively. Both ziprasidone and olanzapine dominated
haloperidol. Results were robust to changes up to10% in the acquisition cost of ziprasi-
done. Inprobabilisticsensitivityanalysis, resultswereconsistentwithbasecase,although
differences between ziprasidone and olanzapine were slighter.CONCLUSIONS: In com-
parison to olanzapine and haloperidol, ziprasidone is associated to the lowest costs
in the treatment of acute agitation episodes in schizophrenic patients in the Mex-
ican setting, as well as better clinical performance than haloperidol.
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OBJECTIVES: We conducted a pharmacoeconomic analysis to determine the cost-
effectiveness of atypical antipsychotic long acting treatments in Croatia.
METHODS: A 1-year decision-analytic framework modeled drug use in chronic
schizophrenia. We determined the average direct cost to the Croatian Institute for
Health Insurance of using treatment pathways that includes depot formulations of
paliperidone (PP-LAI), risperidone (RIS-LAI) or olanzapine (OLZ-LAI) long acting
treatments. The decision tree was populated with guidance from an expert panel
along with literature-derived clinical rates. Costs were obtained from published
lists and adjusted to 2012 euros using the Croatian consumer price index. Clinical
outcomes included quality-adjusted life-years (QALYs), hospitalization rates,
emergency room treatment rates, and relapse days. The outcome of interest was
the incremental cost/QALY gained. RESULTS: Total direct costs to treat one patient
for one year were €4958 for PP-LAI, €5117 for RIS-LAI, and €6429 for OLZ-LAI. Re-
spective QALYs were 0.817, 0.805 and 0.812. PP-LAI dominated the other choices as
it had a lower cost and higher QALY score. PP-LAI was associated with 34.5 relapse
days, 0.252 hospitalizations and 0.127 emergency room visits; OLZ-LAI had 38.4
relapse days, 0.280 hospitalizations and 0.142 emergency room visits; RIS-LAI had
41.1 relapse days, 0.305 hospitalizations and 0.146 emergency room visits. Results
were sensitive against RIS-LAI with respect to drug costs (i.e., if PP-LAI cost in-
creased by 10% or RIS-LAI decreased by 14%) and to OLZ-LAI (i.e., a 10% change for
either drug) with respect to adherence rates. Overall, results were generally robust;
PP-LAI dominated OLZ-LAI in 72.2% of 10,000 Monte Carlo simulations and domi-
nated RIS-LAI in 87.8%. CONCLUSIONS: PP-LAI was the cost-effective choice which
dominated the others for treating chronic schizophrenia in Croatia. Using depot
paliperidon would reduce the overall costs of caring for SCH patients.
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OBJECTIVES: We determined the cost-effectiveness of long-acting antipsychotic
(LAI) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OLZ-LAI) and ris-
peridone (RIS-LAI) for chronic schizophrenia. METHODS: We adapted a decision
tree analysis from Norway for the Finnish National Health Service. Country-spe-
cific data were sought from the literature and public documents, guided by clinical
experts. Costs of health services and products were retrieved from literature
sources and current price lists. We estimated average costs for treating patients
with each LAI for one year, average remission days, rates of hospitalization and
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